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Summary
Carnitine palmitoyltransferases 1 and 2 (CPTs) facili-
tate the import of long-chain fatty acids into mitochon-
dria. Modulation of the catalytic activity of the CPT
system is currently under investigation for the devel-
opment of novel drugs against diabetes mellitus. We
report here the 1.6 A˚ resolution structure of the full-
length mitochondrial membrane protein CPT-2. The
structure of CPT-2 in complex with the generic CPT in-
hibitor ST1326 ([R]-N-[tetradecylcarbamoyl]-amino-
carnitine), a substrate analog mimicking palmitoyl-
carnitine and currently in clinical trials for diabetes
mellitus treatment, was solved at 2.5 A˚ resolution.
These structures of CPT-2 provide insight into the
function of residues involved in substrate binding
and determination of substrate specificity, thereby fa-
cilitating the rational design of antidiabetic drugs. We
identify a sequence insertion found in CPT-2 that me-
diates membrane localization. Mapping of mutations
described for CPT-2 deficiency, a hereditary disorder
of lipid metabolism, implies effects on substrate rec-
ognition and structural integrity of CPT-2.
Introduction
The carnitine palmitoyltransferase (CPT) system imports
long-chain fatty acids (LCFA) into mitochondria, where
they are metabolized by b oxidation (reviewed in
McGarry and Brown, 1997; Ramsay et al., 2001; Bonne-
font et al., 2004). The rate-limiting step of LCFA import is
the transesterification of acyl-CoA to acylcarnitine by
CPT-1 (Ronnett et al., 2005), which is integrated into
the mitochondrial outer membrane. Several mecha-
nisms for the delivery of acylcarnitine esters from the
cytosol into the mitochondrial intermembrane space
have been proposed (Bebernitz and Schuster, 2002).
The acylcarnitine esters are translocated through the
mitochondrial inner membrane (MIM) via the carnitine/
acylcarnitine transporter (CACT). CPT-2, which is local-
ized at the matrix side of the MIM, transforms the im-
ported acylcarnitine back to acyl-CoA.
*Correspondence: michael.hennig@roche.com
3 These authors contributed equally to this work.The muscle isoform of CPT-1 (M-CPT-1), and to
a lesser extent the liver isoform (L-CPT-1), are inhibited
by malonyl-CoA (Zammit, 1999a), the product of the
committed step of fatty acid synthesis. In contrast, the
activity of the ubiquitously expressed CPT-2 is not
known to be directly regulated by malonyl-CoA or other
intermediates of metabolism (McGarry and Brown,
1997; Nic a’ Bhaird et al., 1993) that could be exploited
for pharmacological modulation of CPT-2 activity.
Pharmacological inhibition of the CPT system by the
glycidic acid derivative etomoxir, an irreversible and
nonisoform-specific active site inhibitor of CPTs, has
been demonstrated to reduce fasting blood glucose in
an animal model of type 2 diabetes mellitus (Barnett
et al., 1992). Oral administration of etomoxir decreased
fasting glucose and ketone body levels in obese nonin-
sulin-dependent diabetes mellitus (NIDDM, i.e., diabe-
tes mellitus type 2) patients (Ratheiser et al., 1991),
and insulin-mediated glucose uptake was observed to
be increased in another study with type 2 diabetic pa-
tients (Hubinger et al., 1992). However, specific inhibi-
tion of L-CPT-1 would be desirable, as this would utilize
the glucose-fatty acid (i.e., Randle) cycle for restoring
glucose homeostasis without affecting mobilization of
ectopic lipid depots in skeletal muscle of adipose type
2 diabetes mellitus patients (reviewed in Anderson,
1998; Randle, 1998; Frayn, 2003; Dulloo et al., 2004).
The identification of L-CPT-1 as a target for the treat-
ment of type 2 diabetes mellitus is further supported
by the finding that inhibition of L-CPT-1 has been shown
to reduce gluconeogenesis (Wolf and Engel, 1985;
Kashiwagi, 1995; Wagman and Nuss, 2001). Inhibition
of L-CPT-1 results in depletion of mitochondrial acetyl-
CoA, which is an allosteric activator of the gluconeo-
genic enzyme pyruvate carboxylase.
In addition to etomoxir, various series of compounds
have been designed that are competitive with substrate
binding to CPT-1 (Bebernitz and Schuster, 2002). These
include the aminocarnitine-related family of emericedins
isolated from the ascomycete fungus Emericella quadri-
lineata (Shinagawa et al., 1987), which were further de-
veloped into more L-CPT-1-specific ureidic acylamino-
carnitine derivatives (Giannessi et al., 2001, 2003). A
representative of the latter, (R)-N-(tetradecylcarba-
moyl)-aminocarnitine (ST1326) is an analog of palmitoyl-
carnitine, the product of CPT-1 and a substrate of CPT-
2. The compound ST1326 is currently in clinical trials at
Sigma-Tau Pharmaceuticals. ST1326 was shown to in-
hibit L-CPT-1 in isolated rat mitochondria with marked
specificity over M-CPT-1 (Giannessi et al., 2003). More-
over, ST1326 caused a pronounced reduction of serum
glucose levels when administered orally to db/db mice
(Giannessi et al., 2003) and was shown to elicit an an-
orexic effect, as well as to inhibit endogenous glucose
production after central administration to rats (Obici
et al., 2003). These features render ST1326 a model
compound for L-CPT-1 inhibition in the treatment of
type 2 diabetes mellitus.
In order to support the discovery of novel antidiabetic
drugs that inhibit the CPT system, we investigated the
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714Figure 1. Amino Acid Sequence Alignment of Rat CPT-2 and Human L-CPT-1
Secondary structure elements (S.S.) are indicated. The residue numbering corresponds to the rat CPT-2 (rCPT-2) precursor, and its mitochon-
drial import sequence is italicized. The CPT-2-specific insert (amino acids 179–208) is underlined. Key residues of the acylcarnitine binding site of
rCPT-2 are in bold letters and are labeled with an asterisk when fully conserved in human liver CPT-1 (hL-CPT-1). Residues are printed in red
when mutations in CPT-2 deficiency have been reported.function and structure of the CPT-2 from rat (rCPT-2).
We expressed full-length rCPT-2 from rat in E. coli. Solu-
bilization and purification of membrane bound rCPT-2
with detergent yielded homogeneous and active en-
zyme. Characterization of the activity of rCPT-2 revealed
inhibition of rCPT-2 in vitro by ST1326, which had previ-
ously been reported to be a specific inhibitor of L-CPT-1
(Giannessi et al., 2003).
We elucidated the binding mode of ST1326 by solving
the crystal structure of full-length rCPT-2 in complex
with ST1326 at 2.5 A˚ resolution. We also solved the
structure of rCPT-2 in the absence of ST1326 at 1.6 A˚
and 2.0 A˚ resolution in two different space groups. We
refer to these structures as uninhibited, as opposed to
‘‘apo,’’ because the high-resolution structure reveals
the presence of a fortuitous ligand in the active site of
rCPT-2. The amino acid sequence of rCPT-2 reveals
a 30 amino acid insert uniquely, to our knowledge and
according to a BLAST database search, found in CPT-2
as compared to CPT-1 isoforms, carnitine acetyltrans-
ferase (CrAT), and carnitine octanoyltransferase (CrOT).
Based on the crystal structure of rCPT-2, we propose
a model for membrane attachment of CPT-2 mediated
by this insert.
The crystal structure of rCPT-2 in complex with the
substrate analog ST1326 reveals an extensive hydrogennetwork involving residues highly conserved between
human L-CPT-1 and rCPT-2 that tightly interact with
the hydrophilic aminocarnitine head group of ST1326.
Furthermore, clear electron density for the hydrophobic
tail of ST1326 accommodated in the acyl binding site is
visible. To our knowledge, the structure of rCPT-2 in
complex with ST1326 shows for the first time the sub-
strate binding mode of LCFA-specific carnitine acyl-
transferases, which are indispensible for the import
of substrates for b oxidation into mitochondria. The
rCPT-2 structure also allows for the correlation of struc-
ture and function of amino acids mutated in CPT-2 defi-
ciency, a hereditary disorder of lipid metabolism.
Results
Biophysical Characterization of CPT-2
Rat CPT-2 was solubilized in detergent micelles and pu-
rified to homogeneity by a two-step purification proto-
col. We chose CPT-2 because of markedly increased
solubility (Murthy and Pande, 1987; Woeltje et al., 1990)
and crystallizability when compared to the integral
membrane protein CPT-1. Human L-CPT-1 and rCPT-2
share 27% identity and 43% similarity in the amino
acid sequence of their catalytic cores, and the catalyti-
cally important residues are fully conserved (Figure 1).
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715Figure 2. Characterization of rCPT-2 Quater-
nary Structure and Activity
(A) Sedimentation equilibrium of rCPT-2 in
1% bOG at 20ºC and 12,000 rpm. The absor-
bance at 280 nm (open circle) is plotted ver-
sus radial distance. The solid line shows the
fit corresponding to an apparent single spe-
cies of 73,471 Da (the theoretical molecular
weight of the construct is 73,470.82 Da) with
a partial specific volume of vbar = 0.760 ml/g
and a solvent density of r = 1.092 g/ml. Re-
siduals of the fitted curve are shown in the
top panel.
(B) Inhibition of purified rCPT-2 activity by
ST1326 (IC50 = 0.24 mM). The 100% activity
control was determined in the absence of
ST1326. Mean values 6 standard deviations
of assay points run in triplicate are depicted.In the final preparative size-exclusion chromatography,
rCPT-2 (c z 14 mg/ml in peak fraction) behaved as a
monomer, and no aggregates could be detected
(data not shown). In the presence of 1% (w/v) n-octyl-
b-D-glucopyranoside (bOG; w1.5-fold CMC concen-
tration), but not in preparations with detergents at
CMC concentration of n-dodecyl-b-D-maltoside (DDM),
or 3-([3-cholamidopropyl]dimethylammonio)-1-propane-
sulfonate (CHAPS), rCPT-2 was found to be monomeric
and monodisperse, as determined by analytical ultracen-
trifugation (Figure 2). The purified enzyme was active as
monomer, and its activity could be inhibited in a concen-tration-dependent manner by ST1326, with an IC50 =
0.24 mM (Figure 2).
Overall Structure of CPT-2
The crystal structure of rCPT-2 was determined by mo-
lecular replacement and was refined to a resolution of
1.6 A˚ (C2221) and 2.0 A˚ (P43212) for the uninhibited enzyme
and 2.5 A˚ (P212121) for the ST1326 complex (Table 1).
The first 31 amino-terminal amino acids, comprising
the His tag and 5 residues of the actual rCPT-2 se-
quence, are disordered in both the uninhibited and the
ST1326 complex structures. The full carboxy terminusTable 1. Data Collection and Refinement Statistics
Uninhibited 1, High Resolution Uninhibited 2 CPT-2/ST1316
Data Collection
Space group C2221 P43212 P212121
Cell dimensions
a, b, c (A˚) 95.2, 97.3, 310.4 67.6, 67.6, 307.3 85.8, 96.2, 124.3
Resolution (A˚)a 23.0–1.60 (1.69–1.60) 23.0–2.00 (2.12–2.00) 50.0–2.50 (2.63–2.50)
Rsym
b 6.2 (21.2) 3.1 (7.4) 13.4 (31.0)
I/sI 14.04 (7.24) 28.04 (14.80) 11.71 (4.19)
Completeness (%) 99.7 (99.8) 99.9 (100) 95.8 (92.0)
Redundancy 6.8 (5.8) 21.8 (18.5) 7.1 (6.8)
Refinement
Resolution (A˚) 23.0–1.6 23.0–2.0 15.0–2.5
Number of reflections 179,022 46,957 32,831
Rwork/Rfree
c 16.5/19.4 17.9/23.5 24.1/29.6
Number of atoms
All 11,449 5,502 5,143
Protein 10,085 4,977 4,963
Ligand/ion n/ad n/a 28
Water 1,364 525 152
B factors
Overall 20.1 21.9 41.0
Protein 18.7 21.0 41.4
Ligand/ion n/ad n/a 27.6
Water 30.1 30.7 31.6
Rms deviations
Bond lengths (A˚) 0.014 0.01 0.013
Bond angles (º) 1.225 1.161 1.502
a Values in parentheses are for highest-resolution shells.
b Rsym = SjI(h)j 2 <I(h)>j/S I(h)j, where I(h)j is the scaled observed intensity of the jth observation of reflection h, and I(h) is the mean value of
corresponding symmetry-related reflections.
c R = SjjFoj 2 jFcjj/SjFoj; Rfree was calculated by using a randomly selected set (5%) of reflections.
d The bOG detergent molecule (mean B = 54.9 A˚2), the two C16 alkyl moieties (mean B = 23.3 A˚2), and the two residual, ectopically bound CoA
molecules (mean B = 37.7 A˚2) were not included in the statistics.
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716Figure 3. Structure of rCPT-2 with ST1326 Bound to Its Active Site
(A–E) ST1326 and its surrounding Fo2 Fc simulated annealing omit electron density map (1000 K; 2s contour level) are depicted in pink, and the
amino and carboxy termini are labeled with blue and red spheres, respectively, in (A)–(C). (A) ST1326 binds at the interface of the amino-terminal
(cyan) and carboxy-terminal (orange) domains of rat CPT-2. Strands b1 and b16 mediate the major domain contact by forming an antiparallel
sheet. (B) The central b strands (blue) are surrounded by a helices (green). (C) Same as (B), but rotated 90º to the back. The CPT-2-specific insert
(red) protrudes from the amino-terminal domain. (D) Surface representation of (C) that shows the entry (orange) to the active site tunnel close to
the insert. (E) Surface in orientation of (C) colored according to electrostatic potential; charges (scale bar: rel. charge/color distribution) were
calculated at neutral pH (MOE; Chemical Computing Group, Inc.). Basic residues lining the insert and the entrance to the active site tunnel
are indicated. (F) Electrostatic potential representation identical to that in (E), with the orientation seen in (B). The arrows indicate the entrance
to the CoA tunnel of the active site.(Thr658) is visible in chain A of the high-resolution struc-
ture of uninhibited rCPT-2 in space group C2221, while
the last residues with interpretable electron density at
the carboxy termini are Ile656 and Lys654 in the tetrag-
onal and the complex crystals, respectively.
The rCPT-2 secondary structure contains 27 a helices
and 18 b strands. Amino-terminal (residues 111–440)
and carboxy-terminal (residues 441–658, plus 32–110)
domains can be assigned to rCPT-2. These domains
consist of a six-stranded, central antiparallel b sheet
and surrounding a helices (Figures 1 and 3). Two of
these b strands (b1, b16) mediate the major domain con-
tact. The loop connecting helices 22 and 23 adopts a
helical conformation in the structures of uninhibited
rCPT-2 and is therefore designated helix 22B. The corre-
sponding region of the ST1326 complex structure is lo-
cated close to a crystal contact, which may interfere
with secondary structure formation. A 30 amino acid
insert (comprising helices a8–10) uniquely, to our knowl-
edge, found in CPT-2 when compared to other carnitine
acyltransferases (29 amino acids in the case of L-CPT-1;
Figure 1) protrudes from the amino-terminal domain.
Despite this insert, the overall topology of rCPT-2 re-sembles the two-domain architecture found in human
and mouse CrAT (PDB codes: 1s5o, Wu et al., 2003,
Govindasamy et al., 2004; 1ndb, Jogl and Tong, 2003;
and 1t7n, Hsiao et al., 2004) as well as CrOT (PDB code:
1xl7, Jogl et al., 2005). These members of the family of
carnitine acyltransferases showw30% identity and 47%
similarity in the amino acid sequence of their catalytic
cores.
The presence of ST1326 caused rCPT-2 to crystallize
in a different crystal form when compared to the uninhib-
ited enzyme, but the structures have similar conforma-
tions, as indicated by an rms distance of 0.38 A˚ between
all equivalent Ca atoms. In all three structures, the active
site residue Arg498 is in the generously allowed region
of the Ramachandran plot, and Leu129 and Asn230 do
not comply with favored geometry of the Ramachandran
plot, as indicated by well-defined electron density for
these residues. Leu129 is the second residue in a type
II reverse turn (equivalent to Ile116 in mouse CrAT,
PDB code: 1t7n), whereas Asn230 is located in a b turn
whose geometry is distorted due to interaction with
neighboring Asp297 and Arg124. Mutation of Arg124 is
associated with inherited CPT-2 deficiency (see below).
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The active site of CPT-2 is located in a Y-shaped tunnel
at the domain interface (Figures 3 and 4). The tripartite
(Nic a’ Bhaird et al., 1993) tunnel consists of binding
sites for the acyl, carnitine, and CoA moieties. In con-
trast to CrAT and CrOT, the acyl tunnel opens to the sur-
face in CPT-2. ST1326 is a noncleavable analog of palmi-
toyl-carnitine, the physiological substrate of CPT-2. The
acyl and carnitine tunnels of the active site of CPT-2 are
occupied by ST1326, whereas the CoA tunnel can be as-
signed by homology modeling based on the complex
structure of CrAT with CoA (PDB code: 1t7q; Figure 4).
The hydrophilic aminocarnitine head group of ST1326
is tightly bound in a hydrogen bond network. The cata-
lytic base His372 forms a hydrogen bond with the
amino-nitrogen (N11) of ST1326, which substitutes the
ester oxygen of the native ligand palmitoylcarnitine.
Ser590 of the Ser-Thr-Ser motif conserved among carni-
tine acyltransferases makes a hydrogen bond to the
carbamoyl oxygen (O13) of the ST1326, which confirms
the role of this motif in positioning the substrate for ca-
talysis to occur. Tyr486, Ser488, and Thr499 of the car-
boxy-terminal domain are directly hydrogen bonded to
the carboxyl oxygens (O9 and O10) of ST1326. Hydro-
gen bonds to the guanidinium group of Arg554 further
stabilize the orientation of Tyr486 and Thr499. Resi-
dues Trp116, Tyr120, and Asp376 of the amino-terminal
domain together with Arg498 fix a conserved water
molecule that interacts with the carboxy group of
ST1326 (Figure 4). Arg498 forms a strong hydrogen
bond with the side chain of Asp376, and its guanidi-
nium group interacts with the main chain carbonyl oxy-
gen of Ser373 in the catalytic loop, thereby positioning
the active site residues in an ideal position for catalysis.
The positively charged tertiary amine of ST1326 is sta-
bilized by cation-pi interactions with the conserved
Phe602.
The hydrophobic tunnel that accommodates the ali-
phatic tetradecanoyl tail of ST1326 is lined by residues
of b strands 1 and 16, which form an antiparallel b sheet
at the domain interface, and the two carboxy-terminal
b strands 17 and 18. A simulated annealing Fo 2 Fc
omit map contoured at 2s shows clear continuous elec-
tron density for the ligand ST1326 bound to the active
site (Figure 3). The b strands forming the hydrophobic
acyl tunnel are moved apart in order to make room for
the extended hydrophobic tail of the substrate analog
ST1326 compared to the closed arrangement in CrAT
and CrOT (PDB codes: 1ndb, 1t7n, and 1xl8). The glycine
residue Gly600, at a position where bulkier residues are
found in CrAT (Met564) and CrOT (Gln552), allows for
binding of LCFA carnitine derivatives to CPT-2, thereby
determining substrate specificity. Glu487 and Glu500 of
CPT-2, which are conserved throughout the carnitine
acyltransferases, have been implicated in substrate
binding and catalysis by means of mutational analysis
(Zheng et al., 2002). The crystal structure of rCPT-2 re-
veals that Glu487 is indeed located in the part of the
active site tunnel that accommodates the (modeled)
CoA. Glu487 and the highly conserved Asp464 form
a negatively charged patch that is probably required
for guiding substrates to the active site. The side chain
of Glu500 interacts with the main chain of conserved
Arg554, which is a crucial component of the hydrogenbond network required for binding the carnitine moiety
of acyltransferase substrates.
The side chains of Tyr120 and the catalytic His372
have very weak electron density in both of the uninhib-
ited structures, but they are both well defined in the
structure of the ST1326 complex. Significant electron
density in the final Fo2 Fc map of the 1.6 A˚ high-resolu-
tion structure indicated the presence of a fortuitous li-
gand in the acyl tunnel of both rCPT-2 molecules in the
asymmetric unit (data not shown). This ligand shows
the same binding mode as the alkyl moiety of ST1326
and was interpreted as a C16 aliphatic chain that may
be part of a palmitate molecule from the bacterial host
metabolism. This ligand can be readily displaced by
substrate or the inhibitor ST1326, as shown by the activ-
ity assay and the well-defined inhibitor occupation ob-
served in the ST1326 complex structure. Those residues
in the active site that interact with the hydrophilic amino-
carnitine head group of ST1326, as well as Ser590, are
moved slightly away from the ligand binding site in the
apo structures. While these residues involved in the hy-
drogen bond network outlined in Figure 1 are not in con-
tact with the fortuitous ligand bound in the acyl tunnel,
no conclusions can be drawn with regard to the config-
uration of residues lining the acyl tunnel in the uninhib-
ited state of CPT-2.
Membrane Association
After cleavage of the amino-terminal mitochondrial tar-
geting sequence, the mature CPT-2 protein is localized
to the matrix site of the mitochondrial inner membrane
(MIM; Ramsay et al., 2001). A model for membrane asso-
ciation of CPT-2 had been proposed (Wieser et al., 2003)
that predicts an a helix (Asp464 to Y479) inserted into the
MIM inner leaf. The secondary structure has been pre-
dicted correctly (a21), but the crystal structure of CPT-2
shows this helix to be an integral component of the
carboxy-terminal domain that is not exposed to the sur-
face to be accessible for membrane binding. Structural
alignment of the amino acid sequence of rCPT-2 with
other acyltransferases clearly accentuates the presence
of a unique, to our knowledge, 30 amino acid insert in
rCPT-2 comprising residues Asn179–Asn208 (Figure 1).
These residues form a pair of antiparallel helices (a9
and a10) that protrude from the catalytic core in the vi-
cinity of both the amino terminus and the CoA tunnel
leading to the center of the active site (Figure 3). Helix
a9 is clearly amphipathic. It carries two large hydropho-
bic residues, Phe188 and Phe194, opposed to the
three positively charged residues Lys189, Arg190, and
Arg194. Helix a10 is predominantly hydrophobic. As
CrAT and CrOT lack the insert and are soluble proteins,
the insert most likely confers the membrane association
of CPT-2. This notion is supported by electron density
that indicates the presence of a bOG detergent molecule
interacting with Val195, Leu199, and Tyr202 of helix a10
in chain B of the high-resolution (1.6 A˚) rCPT-2 structure.
CPT-2 Deficiency
The clinically heterogeneous disease CPT-2 deficiency
is caused by various mutations in the CPT-2 gene and
is inherited in an autosomal recessive manner (Bonne-
font et al., 1999, 2004). Two different manifestations of
the disorder can be distinguished based on the time of
Structure
718Figure 4. Reaction Scheme and Protein-
Ligand Interaction Plot
(A) Reaction catalyzed by the CPT system.
Acylcarnitin esters produced by CPT-1 are
transported through the inner mitochondrial
membrane (MIM) by the carnitine/acylcarni-
tine translocase (CACT). CACT also redirects
the carnitine released by CPT-2 into the cyto-
sol.
(B) Stereofigure (generated with MOLOC;
Gerber, 1992) of the tripartite active site tun-
nel with bound ST1326 viewed perpendicular
to the domain interface. Key active site resi-
dues are depicted in yellow. The cocrystal-
lized ST1326 is shown in pink. The CoA mol-
ecule (blue) was modeled based on the CoA
coordinates from the CrAT-CoA complex
structure (PDB code: 1t7q). The protein envi-
ronment of the modeled CoA molecule was
omitted for figure clarity.
(C) Projection of ST1326 (pink) with atom
numbering as used in the text. Key interac-
tions of the hydrogen bond network (red
dashed lines) and with hydrophobic residues
(green) are depicted.
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Category Mutation Clinical Phenotype
Conservation
CPT-1 CrAT CrOT
Substrate binding S113L A
Y120C
E174K A
E454X D
E487K
I502T V V
Structure/domain contact of amino terminus
residues D32–S110
P50H A
L72F (M/B)
R161W A
K164X R or H
Amino-terminal domain R124Q/R124X
N146T
R151Q I
P227L I
K274M
Y290X
R296Q/R296X
D328G I E E
R382K I H
F383Y I
Domain interface D213G
M214T
P604S
Y628S I
Carboxy-terminal domain F448L
Y479F
R503C
G549D
Q550R (B)
D553N
D608H (L/M)
R631C I/A
Insert Y210D
Internal salt bridges affected by mutations (bold face) described for CPT-2 deficiency are: R124–D232, R161–D390, R296–D353, R350–D328,
R382–E174, R503–D553, R631–D608, and D608–H584. All of the affected residues are conserved between rat and human CPT-2; residue num-
bering for the human and rat isoforms of CPT-2 are identical. Homozygous mutations labeled ‘‘A’’ are associated with the late-onset, adult form of
CPT-2 deficiency, and those labeled ‘‘I’’ are associated with the early-onset, infantile phenotype. Residues that are conserved in other carnitine
acyltransferases are highlighted by a gray box. ‘‘B,’’ ‘‘L,’’ or ‘‘M’’ in parentheses indicate conservation limited to brain, liver, or muscle CPT-1,
respectively. Conservative amino acid exchanges are indicated with one-letter code abbreviations.onset, i.e., the early-onset (neonatal or infantile) and the
more frequent adult form of CPT-2 deficiency. The early-
onset form is characterized by a severe symptomatology
including cardiomyopathy and hypoketotic hypoglyce-
mia and has been linked to acute liver failure in sudden
infant death syndrome (Demaugre et al., 1991). Clinical
signs of adult CPT-2 deficiency are recurrent myalgia
and myoglobinuria in response to fasting and exercise.
More than 30 point mutations in the coding region for
CPT-2 leading to single amino acid exchanges in the en-
zyme have been identified (Figure 1 and Table 2), in ad-
dition to deletions/insertions causing frame shifts or
truncation of the protein. Whereas deletions/insertions
in the CPT-2 gene inevitably lead to a severe neonatal
presentation of CPT-2 deficiency by loss of CPT-2 func-
tion, a graduated correlation of genotype and severity of
clinical phenotype becomes obvious for those missense
mutations that have been described in a homozygous
state (Table 2 and Figure 5; Bonnefont et al., 1999; Thuil-
lier et al., 2003). An exception to this correlation is the
mutation of Arg631 to cysteine, which has been identi-
fied in homozygous patients both with the adult as well
as with the infantile form of CPT-2 deficiency. The crys-
tal structure of rCPT-2 allows for mapping and interpre-tation of the effects of the described mutations. Most
(60%) cases of adult CPT-2 deficiency are associated
with a mutation Ser113 to leucine (Taroni et al., 1993).
Ser113 is located at the amino terminus of helix a5 close
to the domain interface. Mutation of Ser113 to a larger,
hydrophobic Leu alters the interaction with the neigh-
boring Phe117. This changes the position and environ-
ment of the catalytically important residues Trp116
and Arg498, rendering the enzyme less active.
Asp213 and Glu487 are affected by naturally occurring
mutations and have been determined to be important for
CPT-2 function by biochemical analyses (Zheng et al.,
2002; Liu et al., 2005). Asp213 is located in a loop be-
tween b3 and a10 of CPT-2 and aligns with a cysteine
conserved in all human CPT-1 isoforms. Mutation of
this cysteine to Ala fully abolishes enzyme activity in hu-
man M-CPT-1, indicating that this position is crucial for
the structural integrity in all CPT isoforms. In CPT-2, the
side chain of Asp213 makes a strong interaction with the
main chain nitrogen of His496. This is important for the
positioning of Arg498 and Thr499, which are important
for substrate binding. Mutation of Glu487 in b13 to as-
partic acid leads to an almost complete loss of CPT-2
activity. This mutation could interfere with CoA binding,
Structure
720Figure 5. Homozygous Mutations in CPT-2
Deficiency
Stereo representation showing the position of
homozygous mutations described for human
CPT-2 deficiency (blue spheres, adult onset;
red spheres, infantile onset; purple, homozy-
gous states reported for both presentations)
mapped onto a ribbon plot of the rCPT-2
structure (color code is as in Figure 3).as Glu487 is part of the CoA tunnel surface. From the
CPT-2 crystal structure, it can be predicted that an as-
partic acid at position 487 would form a strong hydrogen
bond with the side chain of Thr589 of the conserved STS
motif, thereby distorting the geometry of the active site.
A Glu487/Lys exchange is one of six mutations identified
in CPT-2 deficiency that cause disruption of internal salt
bridges or hydrogen bond interactions that are fully con-
served in CPT-1, CrAT, and CrOT (Table 2). A guanidi-
nium nitrogen of Arg296 makes a strong (2.7 A˚) contact
with a side chain oxygen of Asp353, which is conserved
in carnitine acyltransferases. The equivalent residue in
M-CPT-1, Asp454, has been proposed to be part of
a catalytic triad (Liu et al., 2005), whereas the CPT-2
crystal structure implicates this residue in the formation
of a conserved salt bridge. None of the reported mutants
identified in CPT-2 deficiency is located in the insert
mediating membrane localization, although they are dis-
tributed uniformly in the rest of the structure.
Discussion
The crystal structure of rCPT-2 in complex with ST1326
reveals the molecular details of protein-substrate inter-
actions of an LCFA-specific acylcarnitine transferase.
The key residues of the active site that form an extensive
hydrogen network with the aminocarnitine head group
of ST1326 (or a physiological LCFA-acylcarnitine sub-
strate) are fully conserved between rCPT-2 and the can-
didate diabetes drug target L-CPT-1. The sequence
alignment of rCPT-2 and L-CPT-1 shows that L-CPT-1
contains an extended loop between b15 and b16 (Fig-
ure 1), which forms part of the acyl tunnel, and that hu-
man L-CPT-1 has discrete amino acid exchanges in
the acyl tunnel when compared to human (data not
shown) and rCPT-2. Therefore, the structure of rCPT-2
with bound ST1326 is valuable for guiding the develop-
ment of novel drugs for the treatment of type 2 diabetes
mellitus in terms of optimizing affinity and isoform spec-
ificity of pseudo substrates as inhibitors of L-CPT-1.
Investigation of the tissue (liver) exposure and distri-
bution of ST1326, as well as its capability to be trans-
ported into mitochondria by CACT, is needed to eluci-
date the effect of this compound on inhibition of the
ubiquitous CPT-2. Accumulation of ST1326 in hepato-cytes or negligible transport via CACT would greatly in-
crease the safety of ST1326.
The complete inhibition of the CPT system could po-
tentially inflict symptoms of CPT deficiency on diabetic
patients. Therefore, it should be emphasized that down-
regulation rather than complete inhibition of the activity
of L-CPT-1 in diabetic patients is anticipated in order to
restore their gluconeogenesis rate to normal levels.
In addition to the insert of CPT-2 serving as a direct
membrane anchor, a means for membrane localization
could be the recruitment of CPT-2 to the membrane by
physical interaction with CACT. A representation of the
charge distribution on the surface of CPT-2 reveals an
excess of positive charges in the vicinity of the largely
apolar insert and the entrance of the CoA tunnel (Fig-
ure 3). Like other integral membrane proteins, CACT is
known to require the negatively charged mitochondrial
lipid cardiolipin for activity (reviewed in Rubio-Gozalbo
et al., 2004; Palsdottir and Hunte, 2004). The positively
charged and oblate surface of CPT-2 facing the mem-
brane would be ideally suited for interaction with cardi-
olipin molecules that surround CACT. With regard to
this, it is important to note that the MIM inner aspect
consists almost exclusively of esterified, electrically
neutral lipids (phosphatitylethanolamine, phosphatidyl-
choline). With the insert bound to CACT, the CoA tunnel
would be oriented perpendicular to the membrane,
which would allow for direct channeling of acylcarnitine
substrates from CACT into the active site of CPT-2. As
the acyl tunnel does not open to the surface in CrAT
and CrOT, it seems reasonable that the substrates of
carnitine palmitoyltransferases enter the active site via
the CoA tunnel. This mechanism for membrane recruit-
ment of CPT-2 fully supports the observation that acyl-
carnitine esters transported into the mitochondrial
matrix by CACT do not equilibrate with the bulk acylcar-
nitine pool in the mitochondrial matrix (Murthy and
Pande, 1985; reviewed in Zammit, 1999b). Physical as-
sociation of CACT and CPT-2 would allow the carnitine
released by CPT-2 to be transported back into the cyto-
sol by CACT, whereas the newly formed acyl-CoA esters
are directed toward b oxidation. CPT-2 has been copuri-
fied with enzymes of the b oxidation pathway (Kerner
and Bieber, 1990). Therefore, CACT and CPT-2 form
a microenviroment for efficient substrate channeling.
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nal residue of the rCPT-2 structure, is situated in the vi-
cinity of helix a10 of the insert. His44 of the amino termi-
nus directly interacts with the main chain carbonyl
oxygens of Ile192 and Val195 located within the insert.
Therefore, the amino terminus of rCPT-2 is situated in
proximity to the insert. These observations also argue
for the insert mediating membrane localization, because
all CPT-1 isoforms have an amino-terminal domain with
two transmembrane segments (McGarry and Brown,
1997; Ramsay et al., 2001; Price et al., 2002). Docking
the crystal structure of rCPT-2 to the molecular model
of CACT (Tonazzi et al., 2005) may be useful to verify
a possible direct interaction of CPT-2 and CACT.
The crystal structure of rCPT-2 allows for the precise
allocation of mutants identified in CPT-2 deficiency.
The absence of mutations of active site residues in
CPT-2 deficiency emphasizes the essential function of
CPT-2 for fatty acid metabolism, as a complete loss of
function might not be compatible with life. Determining
the correlation of the effect of an amino acid exchange
to CPT-2 function (i.e., its residual activity) could provide
a means to link a given genotype to the severity of the
corresponding clinical phenotype. CPT-2 deficiency
can be detected in a newborn screening. In the case of
a positive diagnosis, a correlation of structure and func-
tion could help to suggest appropriate dietary measures
to ameliorate the clinical symptoms.
Experimental Procedures
Chemicals for expression, purification, and the activity assay were of
the highest purity grade commercially available and were purchased
from Fluka and Sigma if not stated otherwise.
Protein Expression and Purification
The DNA coding for amino acids 27–658 of rCPT-2 (provided by Prof.
V.A. Zammit, Hannah Research Institute, Ayr, Scotland) was ampli-
fied by PCR and subcloned into a Novagen pET28a vector by using
NdeI and NotI (New England Biolabs) restriction sites. This construct
was used to express full-length rCPT-2 (without the mitochondrial
import sequence, amino acids 1–26 of the rCPT-2 precursor) in
E. coli strain BL21(DE3) at 20ºC. After cell disruption, the lysate (in
50 mM HEPES/NaOH [pH 8], 0.15 M NaCl, 5 mM tris-[2-carboxy-
ethyl]-phosphine [TCEP], 10 mM MgCl2, 30 mg/l DNase I, 30 Tbs./l
Roche Complete protease inhibitor) was adjusted with a 0.1% (v/v)
concentration of Triton X-100. Solubilization and centrifugation
(30.000 3g, 45 min) were followed by immobilized metal affinity
chromatography (IMAC) on a HIS-Select-HC Nickel Affinity Gel.
The detergent was exchanged to 1% (v/v) n-octyl-b-D-glucopyrano-
side (bOG) on the column. The eluate from the IMAC step was sub-
jected to a size-exclusion chromatography column (S200, Amer-
sham Bioscences/GE Healthcare) equilibrated with 25 mM Tris/
HCl (pH 8), 0.15 M NaCl, 2 mM TCEP, 1% (v/v) bOG, 0.02% (w/v)
NaN3. ESI-MS confirmed the identity of rCPT-2 and showed that
the protein was modified by amino-terminal a-N-gluconoylation
(Geoghegan et al., 1999; data not shown). The His tag was not cleav-
able with thrombin. A 10 l fermentation (45 g of biomass) yielded 300
mg electrophoretically pure, monomeric and monodisperse protein.
Analytical Ultracentrifugation
Sedimentation equilibrium runs were performed with an Optima XL-I
analytical ultracentrifuge (Beckman-Coulter) at various speeds at
20ºC. Typical rCPT-2 concentrations were 0.23 mg/ml in a buffer con-
taining 1% bOG. The buffer density (1.092 g/ml) was matched to the
detergent density by adding sucrose, leading to a buffer composition
of 19.4 mM Tris (pH 8.0), 116 mM NaCl, 1.55 mM TCEP, 1% bOG, and
15.75% sucrose. The buffer density was measured with a PAAR den-
sity meter type DMA 4500 (Anton Paar). The equilibrium absorbanceprofiles were recorded after 20 hr at 280 nm. An additional record
taken 2 hr later proved that the equilibrium was reached.
Analysis of the profiles was performed with the Beckman software
package and the program DISCREEQ (Schuck, 1994). Addition of su-
crose leads to hydration and affects the partial specific volume. The
partial specific volume of 0.760 ml/g that was used was obtained
from the arithmetic mean of the value for a fully hydrated protein
(0.787 ml/g; Rickwood and Chambers, 1984) and the value computed
from the sequence of the amino acids (0.732 ml/g; Edsall, 1943).
Activity Assay
The activity of rCPT-2 expressed inE. coli (30 nM enzyme concentra-
tion) was measured for the reverse reaction with a spectrophotomet-
ric assay by using 5,50-dithio-bis-(2-nitrobenzoic acid), DTNB. The
HS-CoA released on the formation of acylcarnitine from carnitine
(500 mM) and palmitoyl-CoA (80 mM) reduced DTNB (300 mM). The re-
sulting 5-mercapto-(2-nitrobenzoic acid) absorbs at 410 nm with
a molar coefficient extinction of 13600 M21cm21. The assay buffer
contained 120 mM KCl, 25 mM Tris/HCl (pH 7.4), 1 mM EDTA, and
ST1326 as indicated in Figure 2B.
Protein Crystallization
Crystals of uninhibited rCPT-2 were obtained at a protein concentra-
tion of 10–20 mg/ml and 21ºC by using hanging drops with 0.15 M
DL-malic acid (pH 7.0), 20% (w/v) PEG 3350 (Index 91, Hampton Re-
search). Soaking these crystals with the inhibitor (R)-N-(tetradecyl-
carbamoyl)-aminocarnitine (ST1326, IUPAC: [3R]-3-[tetradecylami-
nocarbonylamino]-4-[trimethylazaniumyl] butanoate, synthesized
in-house according to Giannessi et al., 2003) or the acyl acceptor
CoA did not produce specifically ligated protein. However, there is
clear electron density for the 30,50-ADP moiety of CoA bound to an
ectopic site in a crystal contact of the orthorhombic 1.6 A˚ resolution
structure. As a concentration of 1% (w/v) bOG is required for stabi-
lizing rCPT-2 during purification and crystallization, the insufficient
soaking could be attributed to partition of ST1326 into detergent mi-
celles or blocking of the active site in the crystals by bOG (Ramsay
et al., 2001). Therefore, ST1316 was cocrystallized with rCPT-2 by
using the modified microbatch method (D’Arcy et al., 2003) with
25% (w/v) PEG 1500 (Index 37, Hampton Research). For complex
formation, rCPT-2 was incubated with a 3-fold molar excess of the
inhibitor ST1326 for 3 hr on ice prior to crystallization. All crystals
were flash frozen in liquid nitrogen after 30 s soaks in mother liquor
supplemented with 25% (w/v) PEG 200 (uninhibited rCPT-2) or by
exchanging excess mother liquor and Al’s oil against 100% (v/v) par-
affin oil (ST1326 complex).
Data Collection and Processing
Data sets for uninhibited rCPT-2 and the ST1326 complex were col-
lected on beam line X10SA at SLS, Villigen, Switzerland. The mea-
surements were performed at 100 K with l = 0.97853 A˚ (uninhibited
tetragonal, Se peak wavelength), l = 97899 (uninhibited orthorhom-
bic), and l = 1.008 A˚ (ST1326). The data sets were processed and
scaled with XDS (Kabsch, 1993). The space groups were determined
as P43212 (uninhibited tetragonal; a = b = 67.6 A˚, c = 307.3 A˚; a = b =
g = 90º; Matthews’ coeff. = 2.4, Matthews, 1968; 1 mol/AU), C2221
(uninhibited orthorhombic; a = 95.2 A˚, b = 97.3 A˚, c = 310. 4 A˚; Mat-
thews’ coeff. = 2.4; 2 mol/AU), and P212121 (ST1326; a = 85.8 A˚, b =
96.2 A˚, c = 124.3 A˚; a = b = g = 90º; Matthews’ coeff. = 3.5; 1mol/AU).
The diffraction of initial crystals of rCPT-2 from conventional bacte-
rial expression was not sufficient for structure determination. In con-
trast, crystals of uninhibited rCPT-2 obtained from material that was
seleno-methionine labeled by standard procedures (Chene et al.,
1995) were of superior diffraction quality, which could be attributed
to improved protein quality due to the different media composition
and bacterial protein expression profile during labeling. When the te-
tragonal crystals were soaked in mother liquor containing CoA, the
space group was changed to the maximal nonisomorphic subgroup
C2221. The XDS rejection statistics report merely 0.3% rejected mis-
fits, which fully supports the choice of P212121 as the correct space
group for the complex crystal despite the rather high value for Rmerge
of 13.1%. Of note, the position of the inhibitor ST1326 is clearly de-
fined due to the extensive interaction with residues in the rCPT-2 ac-
tive site, as indicated by marked peaks in the initial Fo2 Fc and final
Structure
722simulated annealing omit Fo2 Fc electron density maps. Data statis-
tics are summarized in Table 1.
Structure Solution and Refinement
Molecular replacement was performed by using AMoRe in the CCP4
interface (Navaza, 1992; CCP4, 1994). For the ST1326 complex,
a rCPT-2 homology model built with XSAE (C. Broger, F. Hoffmann
La-Roche) based on mouse CrAT (Jogl and Tong, 2003; PDB
code: 1t7n) served as a search model. The solution was refined by
simulated annealing with CNS (Bru¨nger, 1992). The final model
was built by using iterative cycles of model building in MOLOC
(Gerber, 1992), solvent building in autoBUSTER (Roversi et al.,
2000), and refinement in Refmac (Murshudov et al., 1999). Despite
Se labeling, the structures of uninhibited rCPT-2 were also solved
by molecular replacement by using the refined complex structure
as a search model, followed by automated model building with
Arp/wArp (Perrakis et al., 1999) and iterative Refmac and MOLOC
cycles. For the orthorhombic (tetragonal) uninhibited structure,
94.0% (92.7%) of the residues lie in the most favored region and
5.4% (6.8%) lie in the additionally allowed regions of the Ramachan-
dran plot. For the ST1326 complex structure, these values are 88.2%
and 11.3%, respectively. Arg498 (generously allowed region) and
Leu129 and Asn230 (Ramachandran outliers) account for the differ-
ences to 100%. Refinement statistics are summarized in Table 1.
PyMOL (DeLano, 2002) was used for preparing structure representa-
tions. Calculation of the electrostatic potential surface of rCPT- 2
was performed with MOE (Chemical Computing Group, Inc.).
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